Journal of Clinical Endocrinology & Metabolism, Vol 57, 1125-1128, Copyright © 1983 by Endocrine Society

ARTICLES

Biological significance of aromatase activity in human breast tumors

N Tilson-Mallett, SJ Santner, PD Feil and RJ Santen

Human breast carcinomas contain aromatase, the enzyme necessary for the conversion of androgens to estrogens. If present in sufficient amounts, aromatase could catalyze the synthesis of estrogens from plasma steroid precursors and produce high breast cancer tissue concentrations. To determine the biological importance of tumor aromatase, we validated a specific and highly sensitive 3H-labeled water release assay for aromatase and used this to quantitate the amount of estrogen synthesized in vitro in breast tumors. As proof of assay validity, the [3H] water release assay detected 22.7 +/- 0.09 (+/- SEM) pmol/g . h estrogen formed vs. 24.7 pmol/g . h with the direct product isolation assay. Of 61 human breast tumors studied, 48 contained measurable aromatase activity, ranging from 5-70.5 pmol estrone formed/g . h. Three aromatase inhibitors (aminoglutethimide, testololactone, and 4- hydroxyandrostenedione) blocked this activity at concentrations similar to those affecting aromatase activity in other tissues. If biologically important, the estrogen formed locally from aromatase would be expected to stimulate production of the progesterone receptor. Under these circumstances, a positive correlation of progesterone receptor and local estrogen production should be found. In contrast, no significant correlation between aromatase activity and progesterone receptor level was observed (r = -0.27; P = NS). In addition, no correlation between estrogen receptor content and aromatase activity was detected. Finally, the amount of aromatase activity present in most tumors was insufficient to produce biologically meaningful saturation of estrogen receptors. These observations suggested that aromatase, while present in the majority of breast cancer tissues, may only be biologically important in those few tumors with very high aromatase activity.

This article has been cited by other articles:

				S. J. Stanway, P. Delavault, A. Purohit, L. W. L. Woo, C. Thurieau, B. V. L. Potter, and M. J. Reed Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer Oncologist, April 1, 2007; 12(4): 370 - 374. [Abstract] [Full Text] [PDF]

				J. Geisler and P. E. Lonning Aromatase Inhibition: Translation into a Successful Therapeutic Approach Clin. Cancer Res., April 15, 2005; 11(8): 2809 - 2821. [Abstract] [Full Text] [PDF]

				M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition Endocr. Rev., April 1, 2005; 26(2): 171 - 202. [Abstract] [Full Text] [PDF]

				T. Nozawa, M. Suzuki, K. Takahashi, H. Yabuuchi, T. Maeda, A. Tsuji, and I. Tamai Involvement of Estrone-3-Sulfate Transporters in Proliferation of Hormone-Dependent Breast Cancer Cells J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1032 - 1037. [Abstract] [Full Text] [PDF]

				P. E. Goss and K. Strasser Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer J. Clin. Oncol., February 1, 2001; 19(3): 881 - 894. [Abstract] [Full Text] [PDF]

				R. J. Pauley, S. J. Santner, L. R. Tait, R. K. Bright, and R. J. Santen Regulated CYP19 Aromatase Transcription in Breast Stromal Fibroblasts J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 837 - 846. [Abstract] [Full Text]

				M. J. Reed and A. Purohit Breast Cancer and the Role of Cytokines in Regulating Estrogen Synthesis: An Emerging Hypothesis Endocr. Rev., October 1, 1997; 18(5): 701 - 715. [Abstract] [Full Text]

				S. J. Santner, R. J. Pauley, L. Tait, J. Kaseta, and R. J. Santen Aromatase Activity and Expression in Breast Cancer and Benign Breast Tissue Stromal Cells J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 200 - 208. [Abstract] [Full Text] [PDF]